Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer.

Journal of cancer policy - 1 Sept 2024

Pataky Reka E, Weymann Deirdre, Bosdet Ian, Yip Stephen, Bryan Stirling, Sadatsafavi Mohsen, Peacock Stuart, Regier Dean A

Abstract excerpt

BACKGROUND: Mutations in KRAS and NRAS are associated with a lack of response to cetuximab and panitumumab, two biologics used for third-line therapy of metastatic colorectal cancer (mCRC). In British Columbia, Canada, eligibility for cetuximab or panitumumab was first based on single-gene KRAS testing. OncoPanel, a multi-gene next-generation sequencing panel with both KRAS and NRAS, was introduced in 2016. Our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to British Columbia
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to GTP Phosphohydrolases

Share to Neoplasm Metastasis

Share to Panitumumab

Share to Proto-Oncogene Proteins p21(ras)

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 39032558
DOI: 10.1016/j.jcpo.2024.100496

Genes

KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer.PMID 39032558Read ↗

Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.Semantic proximity Read ↗

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.Semantic proximity Read ↗

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Semantic proximity Read ↗

Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?Semantic proximity Read ↗

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.Semantic proximity Read ↗

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.Semantic proximity Read ↗

The Role of Multigene Panel Next-Generation Sequencing Techniques in Managing Patients with Metastatic Colorectal CarcinomaSemantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

Multigene Panel Next-Generation Sequencing Techniques in the Management of Patients with Metastatic Colorectal Carcinoma: The Way Forward for Personalized Treatment? A Single-Center Experience.Semantic proximity Read ↗

Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.Semantic proximity Read ↗

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.